Correlation Between Seres Therapeutics and Xilio Development

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Seres Therapeutics and Xilio Development at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Seres Therapeutics and Xilio Development into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Seres Therapeutics and Xilio Development, you can compare the effects of market volatilities on Seres Therapeutics and Xilio Development and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Seres Therapeutics with a short position of Xilio Development. Check out your portfolio center. Please also check ongoing floating volatility patterns of Seres Therapeutics and Xilio Development.

Diversification Opportunities for Seres Therapeutics and Xilio Development

0.33
  Correlation Coefficient

Weak diversification

The 3 months correlation between Seres and Xilio is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Seres Therapeutics and Xilio Development in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xilio Development and Seres Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Seres Therapeutics are associated (or correlated) with Xilio Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xilio Development has no effect on the direction of Seres Therapeutics i.e., Seres Therapeutics and Xilio Development go up and down completely randomly.

Pair Corralation between Seres Therapeutics and Xilio Development

Given the investment horizon of 90 days Seres Therapeutics is expected to under-perform the Xilio Development. But the stock apears to be less risky and, when comparing its historical volatility, Seres Therapeutics is 3.34 times less risky than Xilio Development. The stock trades about -0.04 of its potential returns per unit of risk. The Xilio Development is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  97.00  in Xilio Development on December 27, 2024 and sell it today you would lose (24.00) from holding Xilio Development or give up 24.74% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Seres Therapeutics  vs.  Xilio Development

 Performance 
       Timeline  
Seres Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Seres Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Xilio Development 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Xilio Development are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Xilio Development displayed solid returns over the last few months and may actually be approaching a breakup point.

Seres Therapeutics and Xilio Development Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Seres Therapeutics and Xilio Development

The main advantage of trading using opposite Seres Therapeutics and Xilio Development positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Seres Therapeutics position performs unexpectedly, Xilio Development can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xilio Development will offset losses from the drop in Xilio Development's long position.
The idea behind Seres Therapeutics and Xilio Development pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Content Syndication
Quickly integrate customizable finance content to your own investment portal